StockDrifts LogoStockDrifts

Jinyang Pharmaceutical 007370

Company
진양제약Jinyang Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2026-05-29

Jinyang Pharmaceutical (007370) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Jinyang Pharmaceutical is dated 2025-06-16; the most recent is 2026-05-29. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea).

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-05-29SELL증여
최윤환
Yunhwan Choi
Chairman-100.0K₩4,270+2.3%₩427M ($297K)
2026-05-29SELL증여
최윤환
Yunhwan Choi
Chairman-100.0K₩4,270+2.3%₩427M ($297K)
2026-05-12SELL장외매도
최윤환
Yunhwan Choi
Chairman-10.0K₩4,625+2.5%₩46M ($32K)
2026-05-11SELL장외매도
최윤환
Yunhwan Choi
Chairman-210.0K₩4,680+3.6%₩983M ($683K)
2025-07-02BUY장외매수
최윤환
Yunhwan Choi
CEO Chairman320.0K₩6,370-19.1%₩2.0B ($1.4M)
2025-06-16BUYCB인수
최윤환
Yunhwan Choi
CEO Chairman171.7K₩6,410-19.7%₩1.1B ($764K)

Frequently asked questions

Who has been buying Jinyang Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in Jinyang Pharmaceutical (007370), most recently on 2026-05-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Jinyang Pharmaceutical have?
Jinyang Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-06-16 to 2026-05-29.
Where does StockDrifts get Jinyang Pharmaceutical insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Jinyang Pharmaceutical. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.